| Autor: |
Lacombe K; Université Pierre et Marie Curie. karine.lacombe@sat.aphp.fr, Valin N, Stitou H, Gozlan J, Thibault V, Boyd A, Poirier JM, Meynard JL, Valantin MA, Bottero J, Girard PM |
| Jazyk: |
angličtina |
| Zdroj: |
AIDS (London, England) [AIDS] 2013 May 15; Vol. 27 (8), pp. 1356-9. |
| DOI: |
10.1097/QAD.0b013e32836138d0 |
| Abstrakt: |
The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12 IU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (n = 9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12 IU/ml at W24 (P < 0.001). No grade 3-4 dermatological side-effects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
